IAVI AND MODERNA LAUNCH TRIAL OF HIV VACCINE ANTIGENS DELIVERED THROUGH mRNA TECHNOLOGY
Are you READY? No! Doesn't matter... It will happen no matter what. IAVI AND MODERNA LAUNCH TRIAL OF HIV VACCINE ANTIGENS DELIVERED THROUGH mRNA TECHNOLOGY JANUARY 27, 2022 IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase 1 trial, IAVI G002 , is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process. The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps